Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Schizophrenia
Clinical trial register · United States · industry-sponsored

Schizophrenia Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 13 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 32 Georgia 28 Florida 27 Arkansas 22 Illinois 22
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Bristol-Myers Squibb6 Neurocrine Biosciences5 Alkermes, Inc.2 Eli Lilly and Company2 Otsuka Pharmaceutical Development & Commercialization, Inc.2
State
California32 Georgia28 Florida27 Arkansas22 Illinois22
All 29 states
Target enrolment
to

Schizophrenia trials in the USA

38 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
BioSignal Solutions LLC
Not applicable
30
California
2027-04
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
472
Arkansas, California, Florida, Georgia, Illinois, Maryland, Ohio, Oklahoma
2026-08-20
Recruiting
Leal Therapeutics, Inc
Phase 1
90
Arkansas, California, Florida, Georgia, Maryland, New Jersey, Texas
2026-08-03
Recruiting
TG Therapeutics, Inc.
Phase 2
60
Arkansas, Texas
2026-07-27
Active, closed
Bristol-Myers Squibb
Observational
3,000
Georgia
2026-05-01
Recruiting
LB Pharmaceuticals Inc.
Phase 3
900
Arizona, Arkansas, California, Florida, Georgia, Illinois, Maryland, Missouri
2026-04-23
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
400
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-04-07
Recruiting
MapLight Therapeutics
Phase 2
500
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2026-03-31
Recruiting
LB Pharmaceuticals Inc.
Phase 3
456
Arkansas, California, Florida, Georgia, Illinois, Missouri, Ohio
2026-03-25
Not yet open
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 1
8
Nebraska
2026-03-20
Recruiting
Novartis Pharmaceuticals
Phase 2
142
Arkansas, California, Florida, Georgia, Illinois, Missouri
2026-03-16
Recruiting
Janssen Research & Development, LLC
Phase 1
64
California, Georgia, Illinois, Michigan, New York, Texas
2026-03-02
Recruiting
Bristol-Myers Squibb
Observational
1,500
Arkansas, California, Florida, Georgia, Illinois, Michigan, Minnesota, Nebraska
2026-02-26
Recruiting
Eli Lilly and Company
Phase 2
450
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-02-10
Recruiting
Bristol-Myers Squibb
Phase 3
166
California, Florida, Georgia, Illinois, Massachusetts, New York, Ohio, Tennessee
2026-01-29
Recruiting
Bristol-Myers Squibb
Phase 4
60
Arkansas, California, Florida, Illinois, Nevada, New Jersey, Pennsylvania, Texas
2026-01-20
Recruiting
Neurocrine Biosciences
Phase 3
560
California, Florida, Georgia, Massachusetts, Mississippi, New Jersey, New York, Texas
2025-12-16
Recruiting
Bristol-Myers Squibb
Observational
300
California, Florida, Illinois, Maryland, Massachusetts, Nebraska, New Jersey, New York
2025-09-22
Recruiting
Bristol-Myers Squibb
Phase 1
131
California, Florida, Georgia, Illinois, New Jersey, Texas
2025-09-03
Recruiting
Neurocrine Biosciences
Phase 4
100
Arkansas, California, Florida, Georgia, Illinois, Nebraska, Ohio, Texas
2025-08-29
Recruiting
Neurocrine Biosciences
Phase 3
284
Arkansas, California, Florida, Georgia, Ohio
2025-08-11
Recruiting
AbbVie
Phase 2
268
Arkansas, California, Maryland, New Jersey, Texas
2025-08-04
Recruiting
Neurocrine Biosciences
Phase 3
600
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Mississippi
2025-07-11
Recruiting
Vanda Pharmaceuticals
Phase 3
400
Arkansas, California, Florida, Georgia, Illinois, Mississippi, Missouri, Nevada
2025-05-14
Recruiting
Neurocrine Biosciences
Phase 3
284
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, New Jersey
2025-05-08
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
538
Arkansas, California, Florida, Georgia, Illinois, Louisiana, Maryland, New Jersey
2025-02-28
Active, closed
Spinogenix
Phase 2
32
California
2024-08-01
Recruiting
Study of ALTO-101 in Patients With Schizophrenia
NCT06502964Schizophrenia, Cognitive Impairment
Alto Neuroscience
Phase 2
82
California, Florida, Georgia, Illinois, Maryland, Massachusetts, New York
2024-06-11
Active, closed
Anavex Life Sciences Corp.
Phase 2
71
New Jersey
2024-03-15
Recruiting
Intra-Cellular Therapies, Inc.
Phase 3
300
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-01-25
Recruiting
Vanda Pharmaceuticals
Phase 4
100
Alabama, Arkansas, Colorado, Georgia, North Carolina, Ohio, Washington
2023-05-24
Recruiting
Alkermes, Inc.
Phase 3
220
Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2022-06-30
Recruiting
Reviva Pharmaceuticals
Phase 3
690
Arizona, Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts
2022-01-24
By invitation
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
NCT04987229Bipolar I Disorder, Schizophrenia
DrugOLZ/SAM
Alkermes, Inc.
Phase 3
236
Alabama, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2021-10-22
Recruiting
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
NCT05025605Schizophrenia, Schizo-Affective Disorder, Schizophreniform; Schizophrenic, Bipolar Disorder I
DrugDexmedetomidine
BioXcel Therapeutics Inc
Phase 1
140
California, Florida, Georgia, Texas
2021-08-27
Recruiting
Gedeon Richter Plc.
Phase 3
330
California, Georgia, Michigan, Mississippi, New York, Ohio, Texas
2019-06-06
Active, closed
ERG Components in Schizophrenia and Bipolar Disorder Type I
NCT03788811Schizophrenia, Bipolar I Disorder
diaMentis Inc.
Observational
300
California, Florida, Massachusetts, New Jersey, New York, Texas
2018-07-05
By invitation
Eli Lilly and Company
Observational
4,000
Pennsylvania
2010-03-03
Rows per page Showing 1–38 of 38
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/schizophrenia

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 13 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 38 of those studies listing the condition Schizophrenia.

How many Schizophrenia trials are recruiting in the US?

29 of the 38 studies on this page are recruiting new participants as of the 13 Oct 2026, 03:16 UTC sync. A further 2 have not yet opened recruitment, 5 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Schizophrenia), 38 studies
PhaseStudiesRecruitingShare
Phase 3161442.1%
Phase 28621.1%
Observational5213.2%
Phase 15413.2%
Phase 4337.9%
Not applicable102.6%

Most active sponsors

Lead sponsors with the most studies (Schizophrenia)
Lead sponsorStudiesRecruiting
Bristol-Myers Squibb65
Neurocrine Biosciences55
Alkermes, Inc.21
Eli Lilly and Company21
Karuna Therapeutics, Inc., a Bristol Myers Squibb company22
LB Pharmaceuticals Inc.22
Otsuka Pharmaceutical Development & Commercialization, Inc.20
Vanda Pharmaceuticals22
AbbVie11
Alto Neuroscience11

Top states

Top states (Schizophrenia), by number of studies with a site there
StateStudies
California32
Georgia28
Florida27
Arkansas22
Illinois22
Maryland12
Texas11
Massachusetts10
New Jersey10
New York7
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.